TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04358133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhydrate de morphine
Description: The experimental group will receive an intravenous titration of morphine followed by a subcutaneous administration of morphine hydrochloride for 24 hours according to a predefined protocol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0,9%,
Description: The control group will receive placebo NaCl 0.9% administered according to the same protocol as the experimental arm
Study: NCT03629756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Zimberelimab is a fully human anti-PD-1 monoclonal antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Zimberelimab is a fully human anti-PD-1 monoclonal antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Zimberelimab is a fully human anti-PD-1 monoclonal antibody.
Study: NCT03696953

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Florajen3
Description: Probiotic combination product One capsule daily by mouth.
Study: NCT01014793

Intervention type: DRUG
Intervention: cabergoline
Description: cabergoline doses were increased at 6-week intervals, starting at 1.0mg/week followed by 2.0 and 3.5mg/week. Hormonal evaluations (IGF-I, GH and PRL) started before the first dose and were repeated at 6-week intervals after each cabergoline dose and after cabergoline withdrawal
Study: NCT01372085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2584702 Reference Formulation
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2584702 Reference Formulation
Description: Administered orally
Study: NCT03239743

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Child will wear and interact with virtual reality headset while waiting for surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Child will receive Midazolam to help with pre-operative anxiety prior to surgery
Study: NCT02816008

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation training with RGS in the clinic
Description: Daily cognitive training with the Rehabilitation Gaming System (RGS) in the clinic during 6 weeks (5 days per week a 30 minutes).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Passive/conventional cognitive training at home.
Description: Daily conventional cognitive rehabilitation at home as recommended by the neurologist during 6 weeks (5 days per week a 30 minutes).
Study: NCT03938623

Intervention type: OTHER
Intervention: Training
Description: Teaching general practitioners to use the patient-centered approach when suggesting colorectal cancer screening
Study: NCT03850314

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glycine
Description: Glycine powder to be dissolved in water.
Study: NCT02360176

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy single port
Description: Bariatric surgery: one incision of 2.5 to 3 cm

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sleeve gastrectomy multi trocar
Description: Bariatric surgery: 4 to 7 incisions of 1 to 2 cm
Study: NCT02478203

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Airtraq
Description: videolaryngoscope for difficult airway

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Airtraq
Description: videolaryngoscope for difficult airway
Study: NCT01302093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Racecadotril Film-Coated Tablet (FCT)
Description: A single 100 mg dose of an experimental Racecadotril FCT administered orally with 240 ml of water, with a 7- day washout between visits
Study: NCT01372085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2584702 Reference Formulation
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2584702 Reference Formulation
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2584702 Test Formulation
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2584702 Test Formulation
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2584702 Test Formulation
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2584702 Test Formulation
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally
Study: NCT01302093

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Racecadotril Capsule
Description: A single 100 mg dose of a marketed Racecadotril capsule administered orally with 240 ml of water, with a 7-day washout between visits
Study: NCT01479699

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Olive leaf extract capsules
Description: Four capsules taken at baseline each containing 4mg oleuropein
Study: NCT02478203

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Airtraq
Description: videolaryngoscope for difficult airway

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glidescope
Description: videolaryngoscope for difficult airway

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Glidescope
Description: videolaryngoscope for difficult airway

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glidescope
Description: videolaryngoscope for difficult airway

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: direct laryngoscopy
Description: gold standart for intubation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: direct laryngoscopy
Description: gold standart for intubation
Study: NCT01531543

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: V.A.C.- Vacuum assisted closure laparostomy (KCI)
Description: Primary Vacuum Assisted Closure (V.A.C.)laparostomy was indicated after surgery in patients with severe peritonitis. VAC laparostomy was performed using sandwich technique (semi-permeable foil - intraabdominal foam - dynamic sutura of the fascia - foam inserted subcutaneously - non-permeable foil) and connected to the active suction of 125mmHg.
Study: NCT04261907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC09/ritonavir group
Description: ASC09/ritonavir(300mg/100mg tablet), one tablet each time, twice daily, for 14 days, +conventional standardized treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lopinavir/ritonavir group
Description: Lopinavir/ritonavir tablets(200mg / 50mg tablet), two tablets each time, twice daily, for 14 days, +conventional standardized treatment
Study: NCT02542553

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral BAL
Study: NCT03268707

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemetric smartphone application
Description: Structured follow up with a telemetric smartphone application

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional follow up
Description: Conventional follow up at physician practice
Study: NCT02899650

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: acute downhill running

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: acute downhill running

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: acute downhill running
Study: NCT01372085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally
Study: NCT00444379

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir
Description: Lopinavir/ritonavir 200/50mg plus Emtricitabine/Tenofovir 200/300mg versus Efavirenz 600mg plus Emtricitabine/Tenofovir 200/300mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir
Description: Lopinavir/ritonavir 200/50mg plus Emtricitabine/Tenofovir 200/300mg versus Efavirenz 600mg plus Emtricitabine/Tenofovir 200/300mg
Study: NCT03223844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine Sulfate
Description: Repeated oral administration of dexamphetamine 0.4mg/KG bodyweight four times.
Study: NCT04061148

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIRSIT
Description: NIRSIT is a device that utilizes Near Infrared Spectroscopy to provide a non-invasive measurement of frontal lobe blood oxygenation over time.

Intervention type: DEVICE
Group type: OTHER
Intervention: NIRSIT
Description: NIRSIT is a device that utilizes Near Infrared Spectroscopy to provide a non-invasive measurement of frontal lobe blood oxygenation over time.
Study: NCT01479699

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Olive leaf extract capsules
Description: Four capsules taken at baseline each containing 4mg oleuropein
Study: NCT02954991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glesatinib
Description: Glesatinib is a small molecule multi-targeted receptor tyrosine kinase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mocetinostat
Description: Mocetinostat is an HDAC inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: nivolumab is a programmed death receptor-1 (PD-1) blocking antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: nivolumab is a programmed death receptor-1 (PD-1) blocking antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: nivolumab is a programmed death receptor-1 (PD-1) blocking antibody
Study: NCT03159338

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet rich fibrin
Description: Platelet rich fibrin will be prepared by taking 20 cc blood and centrifugation with 28000 rpm.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In control group , after spliting the osteotomy site before fixation a placebo gel will be placed
Study: NCT01128608

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 24-Hr Esohpageal pH Monitoring
Description: There will be a 24-hr pH monitoring procedure and two 10-minute infusions each one week apart consisting of high PCO2 solution and 0.1 N HCI solution.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCO2 Acid Perfusion and 0.1N HCI Perfusion
Description: A small tube will be inserted through the nostril and into the esophagus. A mild CO2 solution or a mild saline solution will be administered for aprox. 10 minutes during which you will be asked questions regarding any symptoms you may experience.
Study: NCT04251572

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood sampling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionaires
Description: Included participants will complete a baseline questionnaire at end of treatment (EOT) and a follow-up questionnaire throughout the follow-up period (Table 1). The questionnaires collect information on socio-demographics (age, gender, ethnicity, employment status, education level, housing status, incarceration, medical history and OST), injecting drug use (drugs injected, injection frequency and sharing of needle/syringe, cookers, cotton/filter or water). Details on the received DAA regime including mode of administration (direct observed therapy, pill box, etc.) and self-reported data on treatment adherence will also be recorded.
Study: NCT00176423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: galantamine
Description: see arm/group description

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: galantamine
Description: see arm/group description
Study: NCT03573778

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iHEAL
Description: Women work with a Registered Nurse in 10-18 visits (over 6 months) that focus on 6 inter-related 6 components (areas): Safeguarding, Managing Symptoms, Getting Basics, Cautiously Connecting, Regenerating Family, Renewing Self. Using a standard 3 phase process, and guided by 5 principles, the nurse discusses each of these components with the woman in order to identify the woman's needs, experiences and priorities. The nurse then provides personalized support to assist the woman in address the concerns that she sees as most important for her health and well-being; this support includes linking women to existing services if she chooses.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information about Community Services
Description: Women are provided with information about community services appropriate for women experiencing intimate partner violence and consistent with what service providers might recommend (usual care). Women are encouraged to use this information as they see fit.
Study: NCT03047330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol withdrawal
Description: one injection of open-label intramuscular dose of leuprolide (3.75-mg depot), a gonadotropin-releasing hormone agonist that rapidly suppresses estradiol and temporarily achieves ovarian suppression.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fragmented sleep
Description: Fragmented sleep will be experimentally induced.
Study: NCT02627651

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive and motor assignments
Description: walking on treadmill, performing cognitive assignment; and performing the cognitive assignment while walking .

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cognitive and motor assignments
Description: walking on treadmill, performing cognitive assignment; and performing the cognitive assignment while walking .
Study: NCT02046486

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor 180mg whole tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 180mg crushed and dispersed
Study: NCT00323856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alphanate SD/HT
Description: Plasma-derived preparation of Factor VIII
Study: NCT03740282

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lapiplasty
Description: Patients 14 years through 58 years with symptomatic hallux valgus who are treated with the Lapiplasty System will begin weight-bearing by 3 weeks and follow a defined post-operative protocol.
Study: NCT01450020

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: Receive ACS material

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: educational intervention
Description: Receive ACS material

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: counseling intervention
Description: Undergo PN session

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: survey administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: survey administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies
Study: NCT00702533

Intervention type: DRUG
Intervention: Pentagastrin
Study: NCT03851796

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TEENS+Parents as Coaches
Description: Parents as Coaches teaches parenting strategies to facilitate healthy weight loss in adolescent children; adolescents are in a group based behavioral weight management treatment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TEENS+Parent Weight Loss
Description: Parent Weight loss teaches core behavioral weight loss strategies and techniques for parent weight loss; adolescents are in a group based behavioral weight management treatment.
Study: NCT00353158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: 100mg twice daily for 3 days. Two hours after the last dose of doxycycline is taken in the clinic, on-medication phototesting with ssUVR, UVA, and visible light will be performed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voriconazole
Description: After taking voriconazole for (Bullet)7 days to achieve a steady state of voriconazole for subjects, on-medication phototesting with ssUVR, UVA, and visible light will be performed.
Study: NCT06025617

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diagnostic evaluation at the Diagnostic Clinic for Functional Disorders
Description: The intervention consists of being examined at the Diagnostic Clinic for Functional Disorders. If an FSD diagnosis is established, the patient receives feed-back of on the FSD diagnosis and patient education about the condition. Subsequently, the clinic provides guidance to the GP regarding recommended management and treatment options tailored to each individual patient.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic as usual
Description: Diagnostic as usual consists in being referred to be examined at another existing specialist clinic in the secondary sector, as specified by the patient's GP.
Study: NCT04235777

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT)
Description: A fixed dose of 8 Gy x 3 fractions sequential or concurrent with M7824 and PDS01ADC

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT)
Description: A fixed dose of 8 Gy x 3 fractions sequential or concurrent with M7824 and PDS01ADC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDS01ADC
Description: An initial dose of 16.8 mcg/kg administered subcutaneously every 4 weeks while on M7824 and with or without SBRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDS01ADC
Description: An initial dose of 16.8 mcg/kg administered subcutaneously every 4 weeks while on M7824 and with or without SBRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDS01ADC
Description: An initial dose of 16.8 mcg/kg administered subcutaneously every 4 weeks while on M7824 and with or without SBRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M7824
Description: 1200 mg administered IV every two weeks while on PDS01ADC and with or without SBRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M7824
Description: 1200 mg administered IV every two weeks while on PDS01ADC and with or without SBRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M7824
Description: 1200 mg administered IV every two weeks while on PDS01ADC and with or without SBRT
Study: NCT03821935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Livmoniplimab
Description: Liquid for intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Livmoniplimab
Description: Liquid for intravenous infusion.
Study: NCT02542033

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: treated apple juice with low sugar content
Description: Each study participant consumed 500 mL test juice at the morning of the interventional day. The 500 mL bottle content had to be ingested within 5 minutes. an intravenous catheter was inserted into a forearm vein for blood withdrawal at baseline, directly before (time point 0) and 15, 30, 45, 60, 90 and 120 minutes after starting the ingestion of the test product. From all samples plasma insulin was measured. From the blood samples taken at baseline and 120 minutes after consumption of the test product safety parameters were determined. Capillary blood was taken from the finger pad using a HemoCue® Safety Lancet at baseline (twice) and once directly before (time point 0) and 15, 30, 45, 60, 90 and 120 minutes after ingestion of the test product.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: un-treated apple juice with normal sugar content
Description: Each study participant consumed 500 mL test juice at the morning of the interventional day. The 500 mL bottle content had to be ingested within 5 minutes. an intravenous catheter was inserted into a forearm vein for blood withdrawal at baseline, directly before (time point 0) and 15, 30, 45, 60, 90 and 120 minutes after starting the ingestion of the test product. From all samples plasma insulin was measured. From the blood samples taken at baseline and 120 minutes after consumption of the test product safety parameters were determined. Capillary blood was taken from the finger pad using a HemoCue® Safety Lancet at baseline (twice) and once directly before (time point 0) and 15, 30, 45, 60, 90 and 120 minutes after ingestion of the test product.